Rekha Kumar
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1598922023
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,619 of the $86,796 with a category attached, or 65.2%. Novo Nordisk accounts for 87.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $33,667 and has fallen 99.1% since, to $296 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $567.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$76K
- Merck$4K
- Pfizer$4K
- Novo Nordisk AS$2K
- Lilly USA, LLC$378
- Eli Lilly$139
- plus $324 from 8 others
What the payments were for
- Consulting fees$20,12923%
- Speaking & faculty fees$56,61965%
- Travel & lodging$5,6376%
- Food & beverage$4,3105%
- Education$430%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 119 | $75,758 |
| Merck | 1 | $4,000 |
| Pfizer | 1 | $3,800 |
| Novo Nordisk AS | 6 | $2,398 |
| Lilly USA, LLC | 15 | $378 |
| Eli Lilly | 2 | $139 |
| Sanofi-aventis U.S. LLC | 1 | $108 |
| Mannkind Corporation | 2 | $102 |
| Vivus LLC | 1 | $25 |
| IBSA Pharma Inc. | 1 | $22 |
| Amgen | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$48,694
- Wegovy$9,437
- Tresiba$1,360
- SOLIQUA 100/33$108
How this compares
$86,796 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 196 | $229,185 |
| OzempicSemaglutide | 80 | $103,928 |
| WegovySemaglutide | 16 | $21,465 |
| SynthroidLevothyroxine Sodium | 39 | $5,294 |
| Naltrexone Hcl | 18 | $1,819 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $1,497 |
| Metformin Hcl ErMetformin Hcl | 110 | $1,279 |
| Topiramate | 35 | $674 |
| Bupropion XlBupropion Hcl | 20 | $579 |
| Levothyroxine Sodium | 37 | $535 |
| Armour ThyroidThyroid,pork | 12 | $495 |
| Atorvastatin Calcium | 42 | $473 |
| Liothyronine Sodium | 15 | $462 |
| Metformin Hcl | 24 | $432 |
| Alendronate Sodium | 29 | $193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $378 | $229,185196 claims |
| Novo NordiskOzempic, Wegovy | $75,758 | $125,39396 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.